Furthermore, the activation of PI3K/AKT signaling by COL22A1 in our study complements the findings of Langhans et al., in which the authors demonstrated that PI3K signaling inhibitors curtail the aggressiveness of GBM cells [38]. The gene discussed is AKT1; the disease is glioblastoma.